NASDAQ · BEAMHealthcareBiotechnology

Beam Therapeutics financials

$24.52+1.20%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
Revenue$139.7M$63.5M$377.7M$60.9M$51.8M$24.0K
Gross profit$139.7M$63.5M$377.7M$60.9M$51.8M$24.0K
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%
Operating income-$383.7M-$415.6M-$176.5M-$338.5M-$392.5M-$132.8M
Net income-$80.0M-$376.7M-$132.5M-$289.1M-$370.6M-$195.9M
Net margin−57.2%−593.1%−35.1%−474.5%−714.9%−816120.8%
Diluted EPS$-0.81$-4.58$-1.72$-4.13$-5.77$-4.19
EBITDA-$361.4M-$393.6M-$156.5M-$324.3M-$385.0M-$128.0M
Operating cash flow-$345.1M-$347.2M-$149.2M$41.4M-$66.3M-$95.7M
Free cash flow-$360.0M-$356.2M-$182.9M-$7.5M-$113.1M-$112.1M
Diluted shares98.9M82.3M77.2M70.0M64.2M46.7M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$294.9M$282.0M$435.9M$232.8M$560.0M$162.2M
Short-term investments$950.3M$568.8M$754.0M$845.4M$405.7M$137.5M
Total debt$0.00$0.00$0.00$0.00$5.3M$7.4M
Total assets$1.48B$1.10B$1.46B$1.34B$1.47B$451.7M
Total liabilities$242.8M$370.3M$478.4M$608.2M$647.7M$206.1M
Shareholders' equity$1.24B$733.5M$981.3M$733.5M$826.7M$245.6M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology